好的，各位投资人，晚上好，然后欢迎参加我们的医药每周谈第 236 期，关于 GP MOOC 2026 的海外公司的一个进展。然后我是中银建投医药分析师徐颖翔。然后就是关于整个 Gilead 海外公司的一个情况吧。我们可以看得出来，在整个基于摩根这个期间的话，海外 的药企主要就是在一个专利悬崖的一个压力下面，是加速转型与和与技术兑现。大部分跨 国药企的话，是通过一个大规模的 BD 和并购来平滑自己重磅产品专利的到期的一个销售 冲击。包括默沙东规划 700 亿美元的一个新的产品组合，BMS 的话这几年也完成了 300 亿美元的一个并购交易，阿斯利康的话也是目标在 2030 年能够实现一个 800 亿美元的一 个营收。 因此这几年的话，整个受并购与 BD 还是各家跨国药企最重要的一个战略布局的一个方向， 主要也就是为了应对专利悬崖，同时聚焦高确定性的资产，以及技术平台的一个补强。另 一方面的话，也是整个 AI，从工具也上升到了一个制药的一个核心生产力。成为整个制药 行业的一个核心的驱动，驱动力之一。多家跨国药企，包括礼来、阿斯利康、赛诺菲，都 在 GD Morgan 期间。通过与英伟达以及各种其他的 AI 公司达成 ...

Tech giants Alphabet Inc. and Amazon.com Inc. anchor a dense earnings week, with Alphabet Inc. reporting after close Wednesday and Amazon.com Inc. after close Thursday. Major pharmaceuticals including Eli Lilly and Company, AbbVie Inc., Novartis AG, and Novo Nordisk A/S report pre-market Wednesday. Significant activity in industrials and energy is noted on Tuesday, while insurance, semiconductors, and real estate sectors see multiple reports throughout the week, extending into Next Monday. Disclaimer: This ...

华尔街长期以来预测全球减肥药市场未来十年规模将达 1500 亿美元，而如今这一预期的确定性大幅降 低：诺和诺德与礼来的胰高血糖素样肽 - 1（GLP-1）类减肥药在美国市场降价，自费消费市场的竞争 也日趋白热化。 分析师与投资者表示，市场格局正快速变化 —— 新药物有望入市、仿制药竞争即将到来，这让各方不 得不重新测算减肥药市场的峰值规模及达峰时间。 瑞士贝尔维尤资产管理公司投资组合经理、礼来股东特伦斯・麦克马纳斯指出，新消费市场的定价策略 以及诺和诺德旗下司美格鲁肽仿制药的上市，让市场峰值预期有所下调。他说："或许几年前，没人料 到这一切会来得这么快。" 靶向 GLP-1 激素的强效新型减肥药迎来史无前例的市场需求，曾让分析师预测，到 2030 年代初，全球 减肥药市场规模将达 1500 亿美元，甚至 2000 亿美元。但如今，2030 年的市场规模预测已下调约 30%，至 1000 亿美元左右，部分机构更是将 1500 亿美元的目标达峰时间推迟至 2035 年。 杰富瑞在今年 1 月下调了减肥药市场峰值预期，较 2023 年预测的 2030 年代初超 1000 亿美元下调 20%，至 800 亿美元。 杰 ...

Core Insights - Eli Lilly and Company (NYSE: LLY) is forming a strategic collaboration with Repertoire Immune Medicines, potentially worth up to $1.93 billion, aimed at developing new treatments for multiple autoimmune diseases [2][3]. Group 1: Collaboration Details - Under the agreement, Repertoire will receive an upfront payment of $85 million, with an additional $1.84 billion contingent on development and commercial milestones [3]. - The collaboration includes tiered royalties on future net sales, focusing on therapies that restore the immune system without broad immune suppression [3]. Group 2: Access to Technology - As part of the collaboration, Eli Lilly will gain access to Repertoire's Decode platform, which studies T cell recognition and binding to specific targets on diseased cells [4]. - Repertoire will handle early discovery work, after which Eli Lilly will take over clinical development, manufacturing, regulatory activities, and commercialization [4]. Group 3: Strategic Expansion - Eli Lilly is actively expanding its immunology business through various deals and acquisitions, including the $3.2 billion acquisition of Morphic Holding in 2024 to enhance its inflammatory bowel disease pipeline [5]. - The current immunology portfolio of Eli Lilly includes treatments such as Olumiant, Taltz, and Omvoh, addressing conditions like arthritis, immune-related hair loss, psoriasis, and chronic bowel disorders [6].

Medicare's upcoming coverage of obesity treatments could dramatically expand access to Eli Lilly's (NYSE:LLY) experimental weight-loss pill, orforglipron, CEO Dave Ricks said Friday. Medicare Coverage To Unlock Millions Of Patients In an interview with CNBC, Ricks said that the new policy will allow Medicare beneficiaries to access obesity drugs "immediately following launch" of the company's highly anticipated experimental weight-loss drug, Orforglipron. With 20 million to 30 million Medicare patients p ...

By Maggie Fick, Bhanvi Satija and Mariam Sunny LONDON, Feb 2 (Reuters) - The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U.S. prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly and competition heating up in the cash-pay consumer market. The fast-changing ​landscape, which includes the expected entry of new drugs and generic competition, has led to a recalculation of what the pe ...

Core Viewpoint - The expectation that the global market for obesity drugs would reach $150 billion in the next decade is becoming uncertain due to falling prices for GLP-1 treatments in the U.S. [1] Group 1: Market Expectations - Wall Street's long-held expectation for the obesity drug market is now in question [1] - The anticipated market size of $150 billion may not be achievable as previously thought [1] Group 2: Pricing Trends - U.S. prices for GLP-1 treatments are experiencing a decline [1] - The price drop could significantly impact revenue projections for companies involved in obesity drug development [1]

Market Analysis by covering: Walt Disney Company, Eli Lilly and Company, Alphabet Inc Class A, Amazon.com Inc. Read 's Market Analysis on Investing.com ...

Market Performance - The broad U.S. market started the year positively, with the SPDR® S&P 500® ETF (SPY) posting a gain despite some elevated volatility in the final week of January [1]

Market Performance - S&P 500 increased by 0.3% while Nasdaq decreased by 0.2% this week[1] - Small-cap stocks led the decline with Russell 2000 value down by 1.0% and Russell 2000 growth down by 3.1%[1] - Key sectors showing gains include telecommunications (+9.0%) and technology hardware (+4.6%) while software and services fell by 6.9%[1] Fund Flows - Estimated fund flow for S&P 500 components was -$84.1 million this week, a significant drop from +$5.6 million last week[2] - Major inflows were seen in technology hardware (+$40.3 million) and media and entertainment (+$39.5 million) while software and services experienced outflows of -$106.0 million[2] Earnings Forecast - S&P 500's forward 12-month EPS expectation increased by 0.8% this week, up from 0.2% last week[3] - Notable upward revisions were in technology hardware (+5.6%) and automotive (+3.2%) sectors, while energy saw a downward revision of -2.7%[3] Risk Factors - Economic fundamentals, international political uncertainties, U.S. fiscal policy, and Federal Reserve monetary policy present significant risks[3]